ViewPoint Therapeutics is dedicated to the discovery, development, and commercialization of treatments for protein misfiling diseases, including cataracts. Their initial focus is crystallin biology. To address the global need for new methods to treat cataracts and presbyopia, they are pioneering the development of crystallin stabilizers to stabilize the functional form of the crucial human lens protein alpha-crystallin against accumulated damage. By developing VP1-001 as a small molecule medicine suitable for topical application, Viewpoint hopes to revitalize the treatment paradigm for vision loss associated with presbyopia and cataracts. ViewPoint was founded in July of 2014 based on technology developed in the lab of Jason Gestwicki at the University of Michigan - now professor at UCSF, in collaboration with the lab of Usha Andley at Washington University in St. Louis, and is led by Leah Makley, CSO, and Yevgeny Izrayelit, Director of Chemical Biology.